Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2018 · 10-K
Revenue$60.23M$60.23M−68.2% vs Q4 2017 Net Income-$2.13M-$2.13MN/M vs Q4 2017 EPS Diluted-$0.01-$0.01N/M vs Q4 2017 Gross Profit$5,059,000−0.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$10,462,000−93.2% Free Cash Flowderived$7,389,000−95.2% Margins · derivedGross margin8.4%+5.7 pt vs Q4 2017
Operating margin-0.1%−66.5 pt vs Q4 2017
Net margin-3.5%−68.9 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 21, 2019 · 52 d after period end